| 1984 |
Joined Beecham Pharmaceuticals (currently GSK) |
| 1990 |
Joined Critical Care America, Inc. |
| 1991 |
Joined Amgen Inc. |
| 2012 |
Joined Spectrum Pharmaceuticals, Inc |
| May 2014 |
Joined Daiichi Sankyo, Inc. |
| |
Daiichi Sankyo Administrative & Commercial President, Daiichi Sankyo, Inc.
|
| Jun. 2016 |
Daiichi Sankyo Administrative & Commercial President, Daiichi Sankyo, Inc. |
|
and President & CEO, Luitpold Pharmaceuticals, Inc. (currently
American Regent, Inc.)
|
| Apr. 2019 |
President, Daiichi Sankyo U.S. Holdings, Inc. (to present) |
| |
and President & CEO, Daiichi Sankyo, Inc. (to present)
|
| |
and Daiichi Sankyo Administrative & Commercial President, Daiichi Sankyo, Inc. |
| |
and President & CEO, American Regent, Inc.
|
| Apr. 2021 |
Head of Oncology Business Unit of Daiichi Sankyo Group (to present) |
| Jun. 2025 |
Director of the company (to present) |
| Apr. 2026 |
Head of Global Oncology Business of Daiichi Sankyo Group (to present)
|
| (Material concurrent positions) |
| ・President, Daiichi Sankyo U.S. Holdings, Inc. and President & CEO, Daiichi Sankyo, Inc |